Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: AlienTech who wrote (8116)	5/17/1998 11:31:00 AM
From: KM	Read Replies (2) \| Respond to of 23519

From Streetcom: Vivus (VVUS:Nasdaq), a pioneer in the medical field of impotence treatment, has fallen from a high of 41 last October to around 10 because of difficulties getting a new manufacturing plant online, a slump in new prescriptions and a dispute with the Food and Drug Administration over ads. But the success of Pfizer's (PFE:NYSE) Viagra impotence pill could give new life to the stock. Analyst D. Curtis Hogue of Cruttenden Roth in Irvine, Calif., sets a 1998 price target of $23 for Vivus, thanks to new interest generated by Viagra. Pfizer's treatment won't work for everyone, Hogue says, so there's room for several products in the market, including Vivus' Muse. "Vivus is well-positioned to capitalize on the significant number of erectile dystunction patients who we believe will fail on Viagra," he says, concluding that the stock is "extremely undervalued." In a contrasting opinion, Alan Jacobs, research director at Avalon Research Group in Boca Raton, Fla., is not enthusiastic about Vivus' prospects, mainly because of the way Muse is administered. Viagra is a pill taken orally. Muse is a suppository inserted into the tip of the penis with a plastic applicator. "Before I tried Muse I think I would look around first for another pill," he says. More information can be found at: www.sfgate.com